The effect of Baicalin, a PPARy activator, on erythroid differentiation of CD133+ cord blood hematopoietic stem cells

The effect of Baicalin، a PPARy activator، was investigated on erythroid differentiation of CD133+ cord blood hematopoietic stem cells. The effect of PPARγ agonists (Baicalin and Troglitazone) were evaluated in erythropoiesis. CD133+ cells were isolated from human cord blood using MACS technology and cultured in the medium containing PPARγ agonists in a dose-dependent manner with SCF (20 ng/mL) and Epo (4. 5 u/mL). The morphology of CD133+ cells، cell surface markers (Transferrin receptor and glycophorin A)، and the formation of erythroid colony were assessed with microscopicanalysis، flow cytometry، and colony forming assay، respectively. Microscopic and flow cytometric analysis revealed the differentiation of CD133+ cord blood hematopoietic stem cells to erythroid lineage. Flow cytometry showed that both of the PPARγ agonists were able to diminish significantly Transferrin receptor and glycophorin A positive cell population. The inhibitory effect of PPARγ agonists on erythroid differentiation was dose-dependent. The colonies formation of erythroid was suppressed by both of PPARy agonists; hence، the effect of troglitazone was markedly higher. The inhibitory effect of Troglitazone on colonies formation of Erythroid was also markedly higher than Bicaline. Our findings demonstrated that PPARy agonists modulates erythroid differentiation of CD133+ hematopoietic stem cell; therefore، they might play an important role in regulating normal erythropoiesis in vivo. The inhibitory effect of Baicalin on erythropoiesis should be noted because this herbal remedy mostly is used to treat a wide range of diseases.